Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab plus chemotherapy with or without tislelizumab in HER2-positive advanced gastroesophageal adenocarcinoma
PACTR202407858018896Phase 3Unknown
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3 trial of zanidatamab, sponsored by Jazz Pharmaceuticals plc. Status: unknown.
02
Drugs
zanidatamab
Beyond the preview
Go deeper on PACTR202407858018896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407858018896.